Blood vessel supplying tumor (There is no standard abbreviation for "blood vessel supplying tumor." The most relevant scientific term would be "tumor vasculature" or, in some contexts, "TA" (for tumor angiogenesis), but these are not universally standardized.)

The term “blood vessel supplying tumor” refers collectively to the network formed by new capillaries generated through *tumor-induced angiogenesis*. This process enables malignant tissues—otherwise limited by diffusion—to grow beyond minimal size by recruiting host endothelial cells and supporting structures into an expanding neovasculature. Tumors achieve this primarily by secreting proangiogenic factors like vascular endothelial growth factor A (VEGF-A), which stimulate local endothelial proliferation via receptors such as VEGFR on these cells. The resulting vasculature tends toward structural immaturity—being disorganized, leaky, poorly perfused—which both supports aggressive cancer behavior and impedes effective drug delivery. While “the blood vessels themselves” are not direct molecular targets, their formation depends on several well-characterized proteins that serve as validated points for therapeutic intervention—including monoclonal antibodies against VEGF-A or small-molecule inhibitors targeting its receptors. Antiangiogenic strategies aim either at starving tumors by blocking new supply lines or at normalizing aberrant vessels so that other treatments become more effective.

Other names

Tumor vasculatureTumor blood vesselsNeovasculature in cancerAngiogenic blood vessels

Drugs targeting this system typically: Inhibit proangiogenic signaling pathways such as VEGF/VEGFR axis; Block endothelial cell proliferation/migration required for new vessel formation; Normalize abnormal vasculature to improve perfusion/drug delivery (“vascular normalization”).